Douglas Miehm
Stock Analyst at RBC Capital
(2.59)
# 1,209
Out of 5,182 analysts
61
Total ratings
52.17%
Success rate
3.21%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Maintains: Sector Perform | $10 → $9 | $5.70 | +57.89% | 22 | Apr 27, 2026 | |
| MNKD MannKind | Downgrades: Sector Perform | $7.5 → $3.5 | $2.71 | +29.15% | 5 | Feb 27, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $234 → $235 | $238.19 | -1.34% | 8 | Dec 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $15.81 | +20.18% | 14 | Nov 14, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $16.30 | -7.98% | 11 | Nov 5, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.93 | +437.58% | 1 | Mar 10, 2025 |
Bausch Health Companies
Apr 27, 2026
Maintains: Sector Perform
Price Target: $10 → $9
Current: $5.70
Upside: +57.89%
MannKind
Feb 27, 2026
Downgrades: Sector Perform
Price Target: $7.5 → $3.5
Current: $2.71
Upside: +29.15%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $234 → $235
Current: $238.19
Upside: -1.34%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $15.81
Upside: +20.18%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $16.30
Upside: -7.98%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.93
Upside: +437.58%